pixantrone has been researched along with Lymphoma, B-Cell in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Eyre, TA | 1 |
| Appio, L; Bertolli, V; Bregni, M; Chiarucci, M; Crovetti, G; La Targia, M; Landoni, C; Serio, G; Vassenna, E | 1 |
| Alonso Caballero, C; Barrenetxea Lekue, C; D'Amore, F; Grasso Cicala, S; Herráez Rodríguez, S; Jørgensen, JM; Leal Martínez, I; Leppä, S; Stauffer Larsen, T; Toldbod, H | 1 |
| Dunder, K; Flores, B; Gisselbrecht, C; Hudson, I; Laane, E; Péan, E; Pignatti, F; Salmonson, T; Sjöberg, J | 1 |
| Coiffier, B; Derigs, HG; Kravchenko, S; Makhloufi, KM; Pavlyuk, M; Pettengell, R; Sebban, C; Singer, JW; Theocharous, P; Wang, L; Zinzani, PL | 1 |
| Keating, GM | 1 |
| Allievi, C; Bernareggi, A; Cabanillas, F; Fayad, L; Laffranchi, B; Levine, AM; Lim, ST; Modiano, M; Tulpule, A | 1 |
2 review(s) available for pixantrone and Lymphoma, B-Cell
| Article | Year |
|---|---|
Pixantrone beyond monotherapy: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Isoquinolines; Lymphoma, B-Cell; Mitoxantrone; Prednisone; Rituximab; Salvage Therapy; Vidarabine; Vincristine | 2019 |
Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma.
Topics: Adult; Antineoplastic Agents; Deoxycytidine; Gemcitabine; Humans; Isoquinolines; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Rituximab | 2016 |
2 trial(s) available for pixantrone and Lymphoma, B-Cell
| Article | Year |
|---|---|
Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Humans; Isoquinolines; Lymphoma, B-Cell; Male; Middle Aged; Remission Induction; Rituximab; Salvage Therapy; Topoisomerase II Inhibitors | 2016 |
A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Female; Humans; Isoquinolines; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Methylprednisolone; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Salvage Therapy; Treatment Outcome | 2007 |
3 other study(ies) available for pixantrone and Lymphoma, B-Cell
| Article | Year |
|---|---|
Another disappointment in treating relapsed, refractory high-risk aggressive B-cell lymphomas.
Topics: B-Lymphocytes; Deoxycytidine; Gemcitabine; Humans; Isoquinolines; Lymphoma, B-Cell; Rituximab | 2020 |
Single-Agent Pixantrone as a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Lymph Nodes; Lymphoma, B-Cell; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prednisone; Rituximab; Topoisomerase II Inhibitors; Transplantation, Autologous; Ventricular Function, Left; Vincristine | 2017 |
The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human u
Topics: Adult; Anthracyclines; Drug Approval; European Union; Female; Humans; Isoquinolines; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Meta-Analysis as Topic; Recurrence; Risk Assessment; Treatment Outcome | 2013 |